Table 1.
Characteristic | Adult cohort 1 | Adult cohort 2 | Pediatric cohort |
---|---|---|---|
Age at HSCT (years) | 17–70 | 16–69 | 0–18 |
Mean | 45.8 | 49.1 | 8.7 |
Median | 48.2 | 52.0 | 8.2 |
Number of patients | 141 | 138 | 153 |
Male | 69 (49%) | 68 (50%) | 102 (67%) |
Female | 72 (51%) | 68 (50%) | 51 (33%) |
NA | 0 | 2 | 0 |
Diagnoses | |||
Myeloid malignancies (AML, MDS, MPN) | 97 | 78 | 35 |
ALL | 29 | 22 | 88 |
Plasma cell dyscrasias | 12 | 21 | 0 |
AA/BMF | 3 | 8 | 11 |
PID | 0 | 0 | 8 |
Othera | 0 | 9 | 11 |
Source of transplant (MUD/SIB/haplo) | 111/26/4 | 0/138/0 | 86/64/3 |
Type of transplant (PB/BM/cord/NA) | 121/19/1/0 | 101/33/0/4 | 0/130/23/0 |
Conditioning (MAC/RIC/NA) | 118/23/0 | 93/43/2 | 143/10/0 |
AA aplastic anemia, ALL acute lymphoblastic leukemia, AMLacute myeloid leukemia, BM bone marrow, BMF bone marrow failure, MAC myeloablative conditioning, MDSmyelodysplastic syndrome, MPNmyeloproliferative neoplasm, MUD matched unrelated donor, NA not applicable, PB peripheral blood, PID primary immunodeficiency, RIC reduced-intensity conditioning, SIB Sibling.
aOther diagnoses included eight chronic lymphocytic leukemias, and one prolymphocytic leukemia in adult patients; four non-Hodgkin lymphomas, two Langerhans cell histiocytosis, two solid tumor malignancies, one adrenoleukodystrophy, one betathalassemia, and one osteopetrosis in pediatric patients.